entertainment -WSS

entertainment

author：fashion 2025-09-03 18:44:21 - browse：55517

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

WSS

Biden White House, tech companies launch new safeguards around emerging AI technology

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Reframing the conversation around gain

A new deal aims to ramp up use of AI in rehab care decisions

explore

entertainment

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Biden White House, tech companies launch new safeguards around emerging AI technology

Psychedelics group wrestles with new pharma identity

Biden will tout long

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NYC plans to house migrants on an island in the East River

Drug repurposing or repositioning? The language matters

Biden White House, tech companies launch new safeguards around emerging AI technology

Moonlake's readout produced a cash windfall. Risks remain

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Wikipedia

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

What is the Turing Test that determines if computers can think?

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

It's time to take a new tack for treating Alzheimer's

What is artificial intelligence? Experts weigh in

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

leisure time

entertainment

hotspot

focus